267 related articles for article (PubMed ID: 24140770)
21. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Sepúlveda JM; Belda-Iniesta C; Gil-Gil M; Pérez-Segura P; Berrocal A; Reynés G; Gallego O; Capellades J; Ordoñez JM; La Orden B; Balañá C
Clin Transl Oncol; 2015 Sep; 17(9):743-50. PubMed ID: 26033428
[TBL] [Abstract][Full Text] [Related]
22. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
[TBL] [Abstract][Full Text] [Related]
23. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.
Chamberlain MC; Glantz MJ
Neurosurgery; 2008 Oct; 63(4):720-6; author reply 726-7. PubMed ID: 18981882
[TBL] [Abstract][Full Text] [Related]
24. Preirradiation ifosfamide, carboplatin, and etoposide for the treatment of anaplastic astrocytomas and glioblastoma multiforme: a phase II study.
López-Aguilar E; Sepúlveda-Vildósola AC; Rivera-Márquez H; Cerecedo-Díaz F; Hernández-Contreras I; Ramón-García G; Diegopérez-Ramírez J; Santacruz-Castillo E
Arch Med Res; 2000; 31(2):186-90. PubMed ID: 10880725
[TBL] [Abstract][Full Text] [Related]
25. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
26. [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
Hirota T; Takeuchi M; Iwata A; Kitagawa S; Sato T; Konno K; Sawada K; Kobayashi S; Hamaguchi N; Agata H; Katano N; Fujimoto T
Gan To Kagaku Ryoho; 1998 Feb; 25(3):385-90. PubMed ID: 9492832
[TBL] [Abstract][Full Text] [Related]
27. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
Donfrancesco A; Jenkner A; Castellano A; Ilari I; Milano GM; De Sio L; Cozza R; Fidani P; Deb G; De Laurentis C; Inserra A; Dominici C
Acta Paediatr Suppl; 2004 May; 93(445):6-11. PubMed ID: 15176712
[TBL] [Abstract][Full Text] [Related]
28. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.
Abu-Ghosh AM; Krailo MD; Goldman SC; Slack RS; Davenport V; Morris E; Laver JH; Reaman GH; Cairo MS
Ann Oncol; 2002 Mar; 13(3):460-9. PubMed ID: 11996479
[TBL] [Abstract][Full Text] [Related]
29. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
[TBL] [Abstract][Full Text] [Related]
30. Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
Chamberlain MC; Johnston SK
J Neurooncol; 2010 Jan; 96(2):259-69. PubMed ID: 19593660
[TBL] [Abstract][Full Text] [Related]
31. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.
Fayad L; Ansell SM; Advani R; Coiffier B; Stuart R; Bartlett NL; Forero-Torres A; Kuliczkowski K; Belada D; Ng E; Drachman JG
Leuk Lymphoma; 2015; 56(9):2569-78. PubMed ID: 25651427
[TBL] [Abstract][Full Text] [Related]
32. Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study.
Sanson M; Ameri A; Monjour A; Sahmoud T; Ronchin P; Poisson M; Delattre JY
Eur J Cancer; 1996 Dec; 32A(13):2229-35. PubMed ID: 9038603
[TBL] [Abstract][Full Text] [Related]
33. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
34. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
[TBL] [Abstract][Full Text] [Related]
35. Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study.
Park KJ; Kano H; Iyer A; Liu X; Niranjan A; Flickinger JC; Lieberman FS; Lunsford LD; Kondziolka D
J Neurooncol; 2012 Apr; 107(2):323-33. PubMed ID: 22057917
[TBL] [Abstract][Full Text] [Related]
36. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.
Kushner BH; Modak S; Kramer K; Basu EM; Roberts SS; Cheung NK
Cancer; 2013 Feb; 119(3):665-71. PubMed ID: 22951749
[TBL] [Abstract][Full Text] [Related]
37. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
Zhang G; Huang S; Wang Z
J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
[TBL] [Abstract][Full Text] [Related]
38. A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.
Federico SM; McCarville MB; Shulkin BL; Sondel PM; Hank JA; Hutson P; Meagher M; Shafer A; Ng CY; Leung W; Janssen WE; Wu J; Mao S; Brennan RC; Santana VM; Pappo AS; Furman WL
Clin Cancer Res; 2017 Nov; 23(21):6441-6449. PubMed ID: 28939747
[No Abstract] [Full Text] [Related]
39. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Badruddoja MA; Pazzi M; Sanan A; Schroeder K; Kuzma K; Norton T; Scully T; Mahadevan D; Ahmadi MM
Cancer Chemother Pharmacol; 2017 Oct; 80(4):715-721. PubMed ID: 28808777
[TBL] [Abstract][Full Text] [Related]
40. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Welin S; Sorbye H; Sebjornsen S; Knappskog S; Busch C; Oberg K
Cancer; 2011 Oct; 117(20):4617-22. PubMed ID: 21456005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
